Bernard Fox, Co- founder, President, and CEO of UbiVac, shared Patrick Hwu’s, President and CEO at Moffitt Cancer Center, shared on LinkedIn:
“Incredible news! – T and B cell predictions from an H&E slide!
‘Immunoscore’ testing done without immunohistochemical staining!
Prof. Carlo Bifulco the ROCKSTAR Chief Medical Officer for Genomics at Earle A. Chiles Research Institute / Providence Cancer Institute just gave Tour de force presentation. The future is now.
Rapid prediction of patient outcomes from an H&E. More to be done! But this guy is doing it!
Watch this guy! The Foundation Model he and colleagues developed is already independently validated! This technology will be what pharma needs to personalize therapies that have highest chance to improve patient outcomes.”
Title: Multimodal AI generates virtual population for tumor microenvironment modeling
Authors: Jeya Maria Jose Valanarasu, Hanwen Xu, Naoto Usuyama, Chanwoo Kim, Cliff Wong, Peniel Argaw, Racheli Ben Shimol, Angela Crabtree, Kevin Matlock, Alexandra Q. Bartlett, Jaspreet Bagga, Yu Gu, Sheng Zhang, Tristan Naumann, Bernard A. Fox, Bill Wright, Ari Robicsek, Brian Piening, Carlo Bifulco, Sheng Wang, Hoifung Poon
Title: A whole-slide foundation model for digital pathology from real-world data
Authors: Hanwen Xu, Naoto Usuyama, Jaspreet Bagga, Sheng Zhang, Rajesh Rao, Tristan Naumann, Cliff Wong, Zelalem Gero, Javier González, Yu Gu, Yanbo Xu, Mu Wei, Wenhui Wang, Shuming Ma, Furu Wei, Jianwei Yang, Chunyuan Li, Jianfeng Gao, Jaylen Rosemon, Tucker Bower, Soohee Lee, Roshanthi Weerasinghe, Bill J. Wright, Ari Robicsek, Brian Piening, Carlo Bifulco, Sheng Wang, Hoifung Poon
Title: A foundation model for joint segmentation, detection and recognition of biomedical objects across nine modalities
Authors: Theodore Zhao, Yu Gu, Jianwei Yang, Naoto Usuyama, Ho Hin Lee, Sid Kiblawi, Tristan Naumann, Jianfeng Gao, Angela Crabtree, Jacob Abel, Christine Moung-Wen, Brian Piening, Carlo Bifulco, Mu Wei, Hoifung Poon, Sheng Wang
The Society for Immunotherapy of Cancer (SITC) Annual Meeting is the world’s premier scientific forum dedicated exclusively to advancing cancer immunology and immunotherapy.
SITC’s annual meeting focuses entirely on immuno-oncology – the science of harnessing the human body’s immune system, specifically utilizing T cells, B cells, and natural killer (NK) cells, to target and eradicate malignancies. The event acts as a high-stakes arena for debuting:
- Late-breaking clinical trial data for novel immunotherapies and combination treatments.
- Cutting-edge technologies in spatial biology, computational pathology, and oncology-focused artificial intelligence.
- Next-generation therapeutics, including personalized mRNA cancer vaccines, CAR-T cell therapies, and immune checkpoint inhibitors.
You can also read:
Exploring New Frontiers in Cancer Immunotherapy at SITC26 – Cancer Research Institute
